TB-500 and Thymosin Beta-4 are also prohibited by WADA/USADA under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), applicable at all times both in-competition and out-of-competition TB-500 / Thymosin Beta-4 Clinical Trials: The RGN-352 and RGN-259 Programs RegeneRx Biopharmaceuticals has pursued two clinical development programs for Thymosin Beta-4, providing the most substantial human clinical data available for any TB-500-related compound: RGN-352 (Injectable Thymosin Beta-4 for Cardiac Repair): Phase 1 trial (completed): A double-blind, placebo-controlled study enrolled 40 healthy volunteers across four cohorts of 10 subjects each, testing escalating dose levels of intravenous Thymosin Beta-4 administered daily over 14 days
Signolet I, Chenouard R, Oca F, Barth M, Reynier P, Denis MC, Simard G
It helps to reduce the production of melanin, which can lead to a brighter and more even skin tone
Conversely, a more recent 16-week randomized controlled trial ( n = 58) reported that sulforaphane (approximately 45 mg/day) failed to change the severity of psychotic symptoms compared to placebo using the total Positive and Negative Syndrome Scale (McGuinness and Kim, 2020)
Patients should be aware that research in this area is ongoing, and long-term safety and efficacy data may be limited for certain therapies
Some research suggests low vitamin B12 levels are associated with higher body weight, but more research is needed in this area